Nephros (OTCMKTS: NEPHD) is one of 125 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare Nephros to similar companies based on the strength of its valuation, institutional ownership, dividends, analyst recommendations, risk, profitability and earnings.
Valuation & Earnings
This table compares Nephros and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nephros||$5.69 million||-$3.40 million||-11.11|
|Nephros Competitors||$1.45 billion||$147.44 million||53.41|
Nephros’ competitors have higher revenue and earnings than Nephros. Nephros is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Nephros has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Nephros’ competitors have a beta of 0.97, suggesting that their average stock price is 3% less volatile than the S&P 500.
This table compares Nephros and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
50.2% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 6.8% of Nephros shares are owned by insiders. Comparatively, 15.6% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of current ratings and price targets for Nephros and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical & medical instruments” companies have a potential upside of 16.04%. Given Nephros’ competitors higher possible upside, analysts clearly believe Nephros has less favorable growth aspects than its competitors.
Nephros competitors beat Nephros on 8 of the 10 factors compared.
Nephros Company Profile
Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.